Temasek’s ClavystBio Co-Leads in Post-Surgery Pain Therapies
06 Jun 2025
US$ 20.00
ClavystBio, a Singapore-based life sciences investor backed by Temasek Holding (Pte) Ltd, has co-led the US$57.5 m...
Related Publications
Listen to Japan/South Korea Funds (Subscribers' Weekly 09 Jan 2026)...
Subscribers’ Weekly for the week ending 9 Jan 2026...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.